Table 1 Potential COVID-19-related medically actionable genetic conditions

Conditions associated with an increased susceptibility to medications commonly used in managing COVID-19 and respiratory failure

Long QT syndromes and catecholaminergic polymorphic VT

CASQ2, KCNE1, KCNH2^a,b, KCNQ1^a,b, RYR2^a,b, SCN5A^a,b

G6PD deficiency

G6PD

Malignant hyperthermia susceptibility

CACNA1S^a,b, RYR1^a,b

Conditions that cause reversible metabolic or thrombotic crises that are often induced by severe illnesses

Urea cycle disorders

ASL, ASS1, CPS1, NAGS, OTC^a,b, SLC25A13^b, SLC25A15

Lysinuric protein intolerance

SLC7A7

Fatty acid oxidation disorders

ACADM, ACADVL^b, CPT2, ETFA, ETFB, ETFDH

Acute porphyrias

CPOX, HMBS^b, PPOX

Adrenal insufficiency disorders

AAAS, ABCD1^b, AIRE, LHX4, PCSK1, PROP1

Hereditary thrombophilia

PROC^b, PROS1^b, SERPINC1

Methylmalonic acidemia

MMACHC^b, MMADHC^b

Atypical hemolytic uremic syndrome

C3, CD46, CFB, CFH, CFI

Conditions that cause reversible cardiopulmonary complications that can be exacerbated during severe illnesses

Familial cardiomyopathies

ACTC1^a,b, DSC2^a,b, DSG2^a,b, DSP^a,b, LMNA^a,b, MYBPC3^a,b, MYH7^a,b, MYL2^a,b, MYL3^a,b, PKP2^a,b, PRKAG2^a,b, TMEM43^a,b, TNNI3^a,b, TNNT2^a,b, TPM1^a,b, TTN

Cystic fibrosis

CFTR

Refsum disease

PEX7, PHYH

Familial pulmonary hypertension

BMPR2^b

Congenital myasthenic syndrome

CHRNA1, CHRNB1, CHRND, CHRNE, COLQ, CHAT, GFPT1, MUSK, DOK7, RAPSN